607 related articles for article (PubMed ID: 20414098)
21. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
22. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB; Hirsch MS
Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
[TBL] [Abstract][Full Text] [Related]
23. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
24. Melan A (A103) is not a marker of mesothelioma.
Ordóñez NG; Shen SS; Zenali M; Deavers MT
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
[TBL] [Abstract][Full Text] [Related]
25. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
26. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
27. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K; Nymoen DA; Reich R; Davidson B
Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
[TBL] [Abstract][Full Text] [Related]
28. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
[TBL] [Abstract][Full Text] [Related]
29. The differential diagnosis of primary peritoneal papillary tumors.
Gitsch G; Tabery U; Feigl W; Breitenecker G
Arch Gynecol Obstet; 1992; 251(3):139-44. PubMed ID: 1376598
[TBL] [Abstract][Full Text] [Related]
30. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
[TBL] [Abstract][Full Text] [Related]
31. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Ordóñez NG
Mod Pathol; 2013 Aug; 26(8):1132-43. PubMed ID: 23503645
[TBL] [Abstract][Full Text] [Related]
32. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
Kennedy AD; King G; Kerr KM
J Clin Pathol; 1997 Oct; 50(10):859-62. PubMed ID: 9462271
[TBL] [Abstract][Full Text] [Related]
33. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma.
Davidson B; Risberg B; Berner A; Bedrossian CW; Reich R
Semin Diagn Pathol; 2006 Feb; 23(1):35-43. PubMed ID: 17044194
[TBL] [Abstract][Full Text] [Related]
34. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
[TBL] [Abstract][Full Text] [Related]
35. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract.
Tong GX; Memeo L; Colarossi C; Hamele-Bena D; Magi-Galluzzi C; Zhou M; Lagana SM; Harik L; Oliver-Krasinski JM; Mansukhani M; Falcone L; Hibshoosh H; O'Toole K
Am J Surg Pathol; 2011 Oct; 35(10):1473-83. PubMed ID: 21934480
[TBL] [Abstract][Full Text] [Related]
36. So-called peritoneal implants of ovarian carcinomas. Problems in differential diagnosis.
Dienemann D; Pickartz H
Pathol Res Pract; 1987 Apr; 182(2):195-201. PubMed ID: 3601795
[TBL] [Abstract][Full Text] [Related]
37. Well-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.
Erem AS; Allamaneni SS; Braverman TS
Am J Case Rep; 2020 Jan; 21():e920487. PubMed ID: 31929500
[TBL] [Abstract][Full Text] [Related]
38. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
39. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
Raju U; Fine G; Greenawald KA; Ohorodnik JM
Hum Pathol; 1989 May; 20(5):426-36. PubMed ID: 2707793
[TBL] [Abstract][Full Text] [Related]
40. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
